Top brand choice
Strength | Pack Size | Qty | |
---|---|---|---|
Strength
1.25mg/250mg
|
|||
Strength
2.5mg/500mg
|
|||
Strength
5mg/500mg
|
We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!
Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.
To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.
Terms & Conditions of Program
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
GLUCOVANCE (glyburide/metformin) is a combination medication used to treat people with Type 2 Diabetes Mellitus.
People with diabetes do not produce enough insulin to meet their metabolic needs. This may be because the cells of their pancreas are not producing enough insulin, it may be because their body has developed a resistance to insulin, or it can be a combination of both.
GLUCOVANCE helps to lower blood sugar to a safer range, preventing the damage that can be caused by hyperglycemia (high blood sugar).
The starting GLUCOVANCE dosage is 1.25 mg/250 mg by mouth one to two times daily with meals. GLUCOVANCE can be increased to a maximum of 20 mg/2000 mg per day in divided doses.
Take GLUCOVANCE with meals; skipping a meal increases the risk of hypoglycemia.
The active ingredients in GLUCOVANCE are metformin and glyburide.
Metformin decreases the production of glucose by the liver and reduces the absorption of insulin from food.
Glyburide stimulates the cells of the pancreas to release more insulin.
The following medications may have drug-drug interactions with GLUCOVANCE:
Fact Table |
|
Formula |
C27H40Cl2N8O5S |
License |
AU, EU EMA, US FDA |
Bioavailability |
50-60% |
Legal status |
RX Only |
Chemical Name |
Glibenclamide, Metformin |
Elimination half-life |
6.2 hours |
Dosage (Strength) |
1.25mg/250mg (90 tablets), 2.5mg/500mg (90 tablets), 5mg/500mg (90 tablets) |
Pregnancy |
Consult a doctor |
Brands |
Diabeta, Glucovance, Glynase |
Protein binding |
99% |
PubChem CID |
200105 |
MedlinePlus |
a699055 |
ChEBI |
Glibenclamide: 5441, Metformin: 6801 |
ATC code |
None |
DrugBank |
Glibenclamide: DB01016, Metformin: DB00331 |
KEGG |
Glibenclamide: DB00331, Metformin: D04966 |
Routes of administration |
By mouth (tablets) |
GLUCOVANCE can increase the risk of lactic acidosis, a potentially fatal condition where lactic acid in the blood is too high. Avoid excessive alcohol intake while taking GLUCOVANCE. The medication should also be stopped temporarily for any procedure that uses contrast dye.
Use with caution if you have a history of cardiovascular disease.
Hypoglycemia (low blood sugar) is a severe side effect of the active ingredient glyburide. Ask your healthcare provider about the signs and symptoms of hypoglycemia.
Common side effects of GLUCOVANCE may include:
Glucovance [package insert].Princeton, NJ: Bristol-Myers Squibb; 2013.